Top Markets
#1 Zora Zora +42.47%
#2 AI XOVIA AI XOVIA +38.52%
#3 Full Moon Full Moon +19.13%
#4 0G 0G +18.66%
#5 Notcoin Notcoin +15.26%
#6 Axelar Axelar +14.32%
#7 Wrapped NXM Wrapped NXM +12.92%
#8 rsERG rsERG +11.77%
#9 ZKsync ZKsync +10.74%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +10.43%
Coin of the day
Zora Zora
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Intercept Pharmaceuticals, Inc. Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

ICPT
Kedudukan dalam Saham #12017
Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the... Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada. The company currently markets Ocaliva, a medication functioning as a farnesoid X receptor (FXR) agonist. This drug is approved for the treatment of primary biliary cholangitis (PBC) in adults, specifically when administered alongside ursodeoxycholic acid. Beyond its existing approved indications, Intercept is actively investigating Ocaliva's potential for additional uses, notably including nonalcoholic steatohepatitis (NASH). Concurrently, it is progressing other drug candidates through various clinical and preclinical stages of development. In a collaborative effort, the company holds a licensing agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. Intercept distributes its products through a dual approach, utilizing both its proprietary commercial organization and a network of external third-party distributors. The company was founded in 2002 and is headquartered in New York, New York.
Harga Saham
$19.00
Disegerakkan terakhir: 2023-11-14
Modal Pasaran
$629.64M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Intercept Pharmaceuticals, Inc. (ICPT)

Kategori

Healthcare
Nisbah P/E bagi Intercept Pharmaceuticals, Inc. (ICPT)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Intercept Pharmaceuticals, Inc., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Intercept Pharmaceuticals, Inc. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.